BioCentury | Aug 2, 2019
Company News

Aug. 2 Company Quick Takes: Daiichi's cancer drug gets U.S. approval, plus BioMarin, Acorda, Stemline and more

...Consensus estimates provided by FactSet. BioCentury Staff Elzonris (tagraxofusp-erzs, SL-401) Inbrija (CVT-301) pexidartinib (PLX3397) Vimizim, elosulfase alfa (BMN 110, bmn-110, galns) Acorda...
BioCentury | Jun 4, 2019
Company News

June 4 Company Quick Takes: Lilly's Emgality gets expanded indication; plus Vimizim, Zerbaxa and more

...1 Jonathan Block, Associate Editor Emgality, galcanezumab-gnlm (LY2951742) Invossa, TissueGene-C (invossa-k inj., tg-c) Vimizim, elosulfase alfa (BMN 110, bmn-110, galns) Zerbaxa...
BioCentury | Apr 13, 2017
Financial News

Galenica financial update

The Galenica Group spun out its pharmacy and consumer healthcare business into Galenica Santé Ltd. (SIX:GALE) via an IPO on the SIX Swiss Exchange. The remaining Galenica Group business is to be renamed Vifor Pharma...
BioCentury | Mar 21, 2017
Company News

Management tracks

The Relypsa Inc. gastrointestinal subsidiary of Galencia Ltd. (SIX:GALN) said President and CEO John Orwin will resign. Scott Garland will be promoted to president effective March 31, and Orwin's resignation as CEO will take effect...
BioCentury | Mar 17, 2017
Company News

FDA issues second CRL for AZ's hyperkalemia candidate

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it received a second complete response letter from FDA for ZS-9 , its candidate to treat hyperkalemia. The pharma said the CRL followed an FDA inspection of the ZS-9 manufacturing facility...
BioCentury | Feb 24, 2017
Financial News

China's Ally Bridge adds European companies to portfolio

Hong Kong's Ally Bridge Group continued to find deals in Europe, announcing it has added Austria's Nabriva Therapeutics AG (NASDAQ:NBRV) and Switzerland's Galenica Ltd. (SIX:GALN) to its portfolio. Ally Bridge declined to disclose specifics but...
BioCentury | Feb 17, 2017
Company News

ChemoCentryx, Galenica deal

ChemoCentryx and Galenica’s Vifor Pharma company added rights in Asia and the Middle East to a 2016 licensing deal to commercialize avacopan (CCX168). Vifor now has rights to the compound worldwide outside of the U.S....
BioCentury | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and a...
BioCentury | Dec 31, 2016

Delivering takeouts

BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking...
BioCentury | Dec 30, 2016
Company News

ChemoCentryx, Galenica deal

ChemoCentryx and the Vifor Pharma Ltd. subsidiary of Galenica expanded a 2016 deal to include ChemoCentryx candidate CCX140 . ChemoCentryx granted Vifor exclusive, worldwide rights, excluding the U.S. and China, to CCX140 to treat rare renal...
Items per page:
1 - 10 of 236